Managing Outsourced Clinical Trials

2018 Archived Content

OVERVIEW | DOWNLOAD BROCHURE | SPEAKERS | KEYNOTES

Cambridge Healthtech Institute’s 4th Annual

Managing Outsourced Clinical Trials

Building Successful Partnerships with Effective Oversight
February 14-15, 2018 | Hyatt Regency Orlando | Orlando, FL

As more clinical trial activities are outsourced to contract research organizations (CROs) and other third-party vendors, sponsors and their partners must form effective and quality partnerships. Effective management of outsourced clinical trials requires realistic and explicit expectations from each partner in the outsourcing relationship as well as effective oversight and the ability to measure partnership and project performance and quality. Cambridge Healthtech Institute’s 4^th Annual Managing Outsourced Clinical Trials conference features case studies and lessons learned from sponsors and CROs on vendor quality and performance in light of the new ICHE6 R2 changes, as well as the outsourcing partnership and working with third party suppliers to achieve more efficient clinical trials.

Wednesday, February 14

11:30 am Registration Open

12:10 pm Bridging Luncheon Presentation: Data and Insights into Site Operations Allow for Better Forecasting and Budgeting of Trials

Noelle_Gaskill Noelle Gaskill, MBA, Vice President, Research Operations, SignalPath, LLC

By leveraging site level tooling to surface nearly real-time operational metrics; sponsors and CROs are better equipped to plan for costs associated with individual sites, manage ongoing trial costs and project future budgets.

12:50 Coffee and Dessert Break in the Exhibit Hall

1:30 Plenary Keynotes

3:00 Valentine’s Day Celebration in the Exhibit Hall, Last Chance for Exhibit Viewing

ENSURING SUCCESSFUL VENDOR PARTNERSHIPS AND QUALITY

4:00 Chairperson’s Remarks

Walter Young, External Partner Engagement & Governance Lead, CSL Behring

4:05 Put Your Money Where Your Mouth Is: Negotiating Win-Win Contract Structures for a Successful CRO Partnership

SondraSmymios Sondra Smyrnios, Vice President, Clinical Operations, Alkermes

4:30 Talk Title to be Announced

Michael Breton, Independent Consultant

4:55 PANEL DISCUSSION: Vendor Quality and Oversight in Light of the New ICH E6 R2 Changes

Diane_Miller Diane Miller, Director, Vendor Management, AbbVie

Rick_OHara Richard O’Hara, Associate Director, Clinical Outsourcing, Endo Pharmaceuticals

Cheryl_Evans Cheryl Evans, Senior Vice President, Clinical & Medical Operations, CRO, Advanced Clinical

Rene A. Stephens, MSHS, Independent Industry Consultant

With increased pressure of the ICH E6 R2 addendum changes on quality and oversight in clinical trials, Sponsors and CROs are concerned with ensuring quality partnerships. This panel will discuss KPIs for vendor quality, quality metrics, and how Sponsors and CROs are approaching their relationships with quality in mind.

5:50 Close of Day

5:50-7:00 pm Track Reception (Sponsorship Opportunity Available)

Thursday, February 15

7:15 am Registration Open

7:45 Breakfast Presentation: Clinical Trial Operations Insights Evolved via Accenture Life Sciences Cloud

Chandi_Kodthiwada Chandi Kodthiwada, Product Manager, Accenture Life Sciences Cloud (ALSC), Accenture

Chances are you have spent a meaningful amount of time on one of the below questions: How do you assess your Clinical Trial operational efficiency? How do I stay on top of Site behavior? How do you maintain Vendor-Oversight? In the presentation, we will go through Accenture Life Sciences Cloud(ALSC) - Clinical Operations Insights Platform(COIP) and our work with Metrics Champion Consortium(MCC) to answer the above questions.

BUILDING MORE EFFECTIVE PARTNERSHIPS

8:30 Chairperson’s Remarks

Eric Forsthoffer, Vice President, Business Development, Bioclinica

8:35 Governance, Oversight and Quality Management with Key Vendors

Sagarika_Bollini Sagarika Bollini, Director, Head of Clinical Partner Management, Central Clinical Planning and Solutions, Global Clinical Operations, Bristol-Myers Squibb

Discuss key components to CRO/sponsor relationship management and building a framework of trust within the partnership. Can we create a culture of engagement, ownership that drives performance driven culture within the partnership? This talk will focus on governance best practices including diagnosing issues/risk and quality management frameworks for oversight.

9:00 Optimizing External Service Provider Relationships

Walter Young, External Partner Engagement & Governance Lead, CSL Behring

MAKING MEANINGFUL SUPPLIER SEGMENTATION

9:25 Supplier Segmentation and Classification: How to Make It Meaningful

Marija Nikolic, Associate Director, Vendor Management, Contracts & Outsourcing, Astellas Pharma Global Development

This presentation will focus on how to go about understanding the true business levers and drivers to make meaningful supplier segmentation. Careful consideration should be given to levers that encompass inherent business risk as well as those that drive value. The segmentation or classification process should be made distinct to clearly drive the message as to the oversight and management of the classification. Meaningful classification translates into recognizable benefits to internal stakeholders.

9:50 Talk Title to be Announced

Rene A. Stephens, MSHS, Independent Industry Consultant

10:15 Networking Coffee Break

10:30 Chairperson’s Remarks

Jens B. Thuesen, CTMS Business Development, BSI Business Systems Integration AG

10:35 Creating Stronger Biopharma-CRO Relationships Through Technology

Anca Copaescu, CEO, Strategikon Pharma

WORKING WITH THIRD PARTY SUPPLIERS

11:00 Contracting Dilemmas - Should the Sponsor or CRO Contract with Third Parties?

Lan Bandara, Director, Pharmaceutical Contract Management Group (PCMG); Director, Clinical Outsourcing, Medicines Development Centre, Coordination Department, Eisai Limited

The talk covers 1. Different contract models, 2. Pros and cons of each model with reference to new ICH E6 R2 guidelines, 3. Lessons learned from recent case studies.

11:25 Brief Session Break

11:35 pm PANEL DISCUSSION: Where Is the Industry Headed with 3rd Party Suppliers?

Bella Sessoms, Director, Development Sourcing Management, Astellas

Charlotte_French Charlotte French, Executive Director, Portfolio Relationship & Sourcing Management, Medical and Development, Astellas

Craig_Coffman Craig Coffman, Executive Director, Clinical Business Operations & Outsourcing, Nektar Therapeutics

Lan Bandara, Director, Pharmaceutical Contract Management Group (PCMG); Director, Clinical Outsourcing, Medicines Development Centre, Coordination Department, Eisai Limited

As CROs are tasked with outsourcing more services on behalf of Sponsor companies, where is the industry headed with this practice? This panel will address the following questions: Are CROs equipped to effectively outsource for additional service providers? When Sponsors outsource to CROs, is the CRO’s capability to outsource additional services a factor in deciding to partner with a particular CRO? How is oversight and accountability of deliverables being handled? What are some best practices and lessons learned when CROs are outsourcing multiple services?

12:50 Closing Remarks

1:00 SCOPE Summit 2018 Adjourns